Cross Biologics

Cross Biologics is a South Korean biotechnology company specializing in the development of next-generation bispecific antibody therapeutics for oncology. The company leverages its proprietary Cross-Body platform to create multi-specific antibodies designed to overcome the limitations of current monotherapies by simultaneously targeting immune checkpoints and costimulatory signals. Its lead candidate, CB-101, is a bispecific antibody targeting PD-L1 and 4-1BB, aimed at enhancing T-cell activity within the tumor microenvironment while minimizing systemic toxicity. Cross Biologics is focused on advancing its immuno-oncology pipeline through preclinical stages to address unmet needs in solid tumor treatment. The company was founded by industry veterans with significant experience in antibody engineering and drug development from leading pharmaceutical firms.